サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1465624

移植のための分子診断

Molecular Diagnostics for Transplant
出版日: | 発行: Market Research Future | ページ情報: 英文 130 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.91円
移植のための分子診断
出版日: 2024年04月10日
発行: Market Research Future
ページ情報: 英文 130 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

移植のための分子診断の市場規模は、予測期間中に8.91%のCAGRで成長すると予測されています。

気候変動、急速な都市化、微生物の進化など、さまざまな要因によって感染症が増加しています。移植患者は細菌、ウイルス、真菌、寄生虫などによるあらゆる種類の感染症にかかる可能性があるため、移植前には特別な注意が必要です。これらには、インフルエンザウイルス感染症、尿路感染症、肺炎球菌性肺炎、サイトメガロウイルス、エプスタインバーウイルス、ヒトヘルペスウイルス6などがあります。また、抗菌薬耐性の増加も深刻な懸念材料であり、感染症の流行に拍車をかけています。このように、感染症が増加していることが、移植における徹底的な分子診断の実施に対する需要を高め、市場を牽引しています。

北米市場は2021年に最大のシェアを示しました。これは技術の進化や、臓器移植の増加につながる慢性疾患の増加によるものです。調査によると、米国では腎臓、肝臓、心臓、肺、膵臓、腸の移植件数が増加しており、カナダでは腎臓移植件数が増加しています。

欧州市場は、腎臓、心血管疾患、呼吸器疾患などの慢性疾患の有病率の上昇により、第2位のシェアを占めています。また、アジア太平洋市場は予測期間中に大きなシェアを得ると予想されています。同地域では老齢人口が増加しており、臓器移植を希望する人が増えています。

当レポートでは、世界の移植のための分子診断の市場を調査し、市場の定義と概要、市場成長への影響因子および市場機会の分析、市場規模の推移・予測、各種区分・地域別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

目次

第1章 エグゼクティブサマリー

第2章 市場概要

第3章 調査手法

第4章 市場力学

  • 概要
  • 促進要因
    • 感染症の蔓延の増加
    • 分子診断技術の進歩
    • 移植手術件数の増加
  • 抑制要因
    • 製品承認に関する厳格な規則と規制
    • 熟練技術者の不足
  • 機会
    • 臓器提供と移植に関する一般の意識の高まり

第5章 市場要因分析

  • バリューチェーン分析
  • ポーターのファイブフォース分析
  • COVID-19が市場に与える影響
  • 感染症ウイルスに関する定性的概要

第6章 世界の移植のための分子診断市場：製品別

  • 概要
  • 試薬・キット
  • 機器
  • サービス・ソフトウェア

第7章 世界の移植のための分子診断市場：技術別

  • 概要
  • ポリメラーゼ連鎖反応（PCR）
  • シークエンシング
  • マイクロアレイ
  • その他

第8章 世界の移植のための分子診断市場：エンドユーザー別

  • 概要
  • 病院・移植センター
  • 研究機関・学術機関
  • その他

第9章 世界の移植のための分子診断市場：地域別

  • 北米
  • 欧州
  • アジア太平洋
  • その他の地域

第10章 競合情勢

  • 概要
  • 競合ベンチマーキング
  • 主要な成長戦略
  • 開発件数でトップの企業
  • 主要開発分析
  • 主な展開・成長戦略
  • 財務マトリックス

第11章 企業プロファイル

  • BIOMERIEUX SA
  • THERMO FISHER SCIENTIFIC INC.
  • CEPHEID
  • ALTONA DIAGNOSTICS GMBH
  • ELITECHGROUP
  • F. HOFFMANN-LA ROCHE LTD
  • HOLOGIC, INC.
  • QIAGEN N.V.
  • BECTON, DICKINSON AND COMPANY
  • ABBOTT

第12章 付録

図表

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030(USD MILLION)
  • TABLE 3 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR REAGENTS & KITS, BY REGION, 2018-2030(USD MILLION)
  • TABLE 4 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR INSTRUMENTS, BY REGION, 2018-2030(USD MILLION)
  • TABLE 5 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SERVICES & SOFTWARE, BY REGION, 2018-2030(USD MILLION)
  • TABLE 6 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030(USD MILLION)
  • TABLE 7 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2030(USD MILLION)
  • TABLE 8 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR SEQUENCING, BY REGION, 2018-2030(USD MILLION)
  • TABLE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR MICROARRAY, BY REGION, 2018-2030(USD MILLION)
  • TABLE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018-2030(USD MILLION)
  • TABLE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030(USD MILLION)
  • TABLE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR HOSPITALS AND TRANSPLANT CENTERS, BY REGION, 2018-2030(USD MILLION)
  • TABLE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2018-2030(USD MILLION)
  • TABLE 14 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, FOR OTHERS, BY REGION, 2018-2030(USD MILLION)
  • TABLE 15 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 17 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 19 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 20 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 21 US MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 22 US: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 23 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 25 CANADA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 26 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 29 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 30 GERMANY MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 31 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 32 GERMANY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 33 UK MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35 UK: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36 FRANCE MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 37 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38 FRANCE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 41 ITALY: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 42 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 44 SPAIN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47 REST OF EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 48 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 49 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 52 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54 JAPAN: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 56 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57 CHINA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 58 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 60 INDIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 61 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63 AUSTRALIA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 64 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 66 SOUTH KOREA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 68 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69 REST OF ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 70 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 71 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 73 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76 MIDDLE EAST: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 79 AFRICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 80 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82 LATIN AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 83 MAJOR PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • TABLE 84 MOST ACTIVE PLAYER IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • TABLE 85 PRODUCT LAUNCH/ PRODUCT APPROVAL
  • TABLE 86 PARTNERSHIP/AGREEMENT
  • TABLE 87 MERGER/ACQUISTION
  • TABLE 88 BIOMERIEUX SA: PRODUCT OFFERED
  • TABLE 89 BIOMERIEUX SA: KEY DEVELOPMENTS
  • TABLE 90 THERMO FISHER SCIENTIFIC INC.: PRODUCT/SERVICE OFFERED
  • TABLE 91 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS
  • TABLE 92 CEPHEID: PRODUCT/SERVICE OFFERED
  • TABLE 93 CEPHEID: KEY DEVELOPMENTS
  • TABLE 94 ALTONA DIAGNOSTICS GMBH: PRODUCTS OFFERED
  • TABLE 95 ALTONA DIAGNOSTICS GMBH: KEY DEVELOPMENTS
  • TABLE 96 ELITECHGROUP: PRODUCTS OFFERED
  • TABLE 97 ELITECHGROUP: KEY DEVELOPMENTS
  • TABLE 98 F. HOFFMANN-LA ROCHE LTD: PRODUCTS OFFERED
  • TABLE 99 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS
  • TABLE 100 HOLOGIC, INC: PRODUCTS OFFERED
  • TABLE 101 HOLOGIC INC.: KEY DEVELOPMENTS
  • TABLE 102 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 103 QIAGEN N.V.: KEY DEVELOPMENTS
  • TABLE 104 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 105 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS
  • TABLE 106 ABBOTT: PRODUCTS OFFERED
  • TABLE 107 ABBOTT: KEY DEVELOPMENTS

LIST OF FIGURES

  • FIGURE 1 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET STRUCTURE
  • FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 3 MARKET DYNAMICS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • FIGURE 4 DRIVER IMPACT ANALYSIS
  • FIGURE 5 RESTRAINT IMPACT ANALYSIS
  • FIGURE 6 VALUE CHAIN ANALYSIS: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • FIGURE 7 PORTER'S FIVE FORCES ANALYSIS: GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • FIGURE 8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY PRODUCT
  • FIGURE 9 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT, 2021 & 2030 (USD MILLION)
  • FIGURE 10 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION)
  • FIGURE 11 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER, 2021 & 2030 (USD MILLION)
  • FIGURE 12 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION 2021 & 2030 (USD MILLION)
  • FIGURE 13 GLOBAL: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY REGION,
  • FIGURE 14 NORTH AMERICA: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY
  • FIGURE 15 EUROPE: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY
  • FIGURE 16 ASIA PACIFIC: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY
  • FIGURE 17 REST OF THE WORLD: MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET SHARE (%), BY COUNTRY
  • FIGURE 18 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 19 MAJOR STRATEGY ADOPTED BY KEY PLAYERS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • FIGURE 20 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET: COMPETITIVE LANDSCAPE
  • FIGURE 21 SALES
  • FIGURE 22 R&D EXPENDITURE,
  • FIGURE 23 BIOMERIEUX SA: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 24 BIOMERIEUX SA: SWOT ANALYSIS
  • FIGURE 25 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS
  • FIGURE 27 F. HOFFMAN LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 F. HOFFMAN LA ROCHE LTD: SWOT ANALYSIS
  • FIGURE 29 HOLOGIC INC.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 30 QIAGEN N.V.: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 QIAGEN N.V.: SWOT ANALYSIS
  • FIGURE 32 BECTON, DICKINSON AND COMPANY : FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS
  • FIGURE 34 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT
目次
Product Code: MRFR/HC/10305-CR

Molecular Diagnostics for Transplant Market Research Report Forecast till 2030

Market Overview

Molecular Diagnostics for Transplant Market is anticipated to register a CAGR of 8.91% during the review period.

Expanding pervasiveness of irresistible illnesses, rising number of transplant systems, and progressions in molecular symptomatic methods are reinforcing the market development.

There has been a rising pervasiveness of irresistible illnesses attributable to different factors, for example, environmental change, quick urbanization, microbial development, among others. Exceptional consideration should be accepted before transplantation as a transplant patient can get any kind of contamination brought about by microorganisms, infections, organisms and parasites. These incorporate flu infection contamination, urinary lot disease, pneumococcal pneumonia, Cytomegalovirus, Epstein-Barr infection, Human herpesvirus 6, among a few others. Besides, expanding antimicrobial obstruction is likewise a reason for serious concern and has been adding to the rising predominance of irresistible infection. For example, as per the Communities for Infectious prevention and Anticipation, more than 2.8 million antimicrobial-safe contaminations happen in the US every year. Subsequently, expanding commonness of irresistible sickness has driven the interest for execution of exhaustive molecular diagnostics in transplantation, in this manner, driving the market.

Market Segmentation

The Molecular Diagnostics for Transplant Market, based on product is segmented into reagents & kits, instruments, and services & software.

Based on technology the market is divided into polymerase chain reaction (PCR), sequencing, microarray, and others.

Based on end user, the market has been classified into the hospitals and transplant centers, research laboratories & academic institutes, and others.

Regional Insights

North America molecular diagnostics for transplant market represented the biggest piece of the pie in 2021, because of rising interest innovation development and expanding rates of ongoing sicknesses that lead to an expansion in organ transplants. As per research, the quantity of kidneys, liver, heart, lung, pancreas, and digestive tract transplants is expanding in the US, while the quantity of kidney transplants is expanding in Canada.

Europe molecular diagnostics for transplant market represents the second-biggest market attributable to the rising pervasiveness of constant infections, including kidney, cardiovascular sicknesses (CVD), and respiratory illnesses. Headways in molecular diagnostics have worked on the recognizable proof and comprehension of explicit quality imperfections for the suitable organ transplant in kidney, heart, and lung disappointment. CVD illnesses are impacted by variables, for example, atherosclerosis, blood clusters, diabetes, a stationary way of life, and weight, which might prompt heart disappointment.

The Asia-Pacific molecular diagnostics for transplant market is supposed to develop at a critical share from 2022 to 2030. The region's developing geriatric populace requests organ transplantation, which might change according to organ disappointment. In 2020, as per the World Financial Forum, China, India, and Japan had the most established populaces universally. Moreover, it has been assessed that by 2050, one of every four matured individuals will be living in the region.

Major Players

Key Companies in the Molecular Diagnostics for Transplant Market are Thermo Fisher Scientific Inc. (US), Abbott Laboratories, Inc. (US), Cepheid (US), Altona Diagnostics GmbH (Germany), ELITechGroup (France), BioMerieux SA (France), Hoffmann-La Roche Ltd. (Switzerland), Hologic Inc. (US), QIAGEN N.V. (Germany), Becton, Dickinson, and Company (US), and Others.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

  • 1.1 OVERVIEW
    • 1.1.1 MARKET SYNOPSIS

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 LIST OF ASSUMPTIONS

3 RESEARCH METHODOLOGY

  • 3.1 OVERVIEW
  • 3.2 DATA MINING
  • 3.3 SECONDARY RESEARCH
  • 3.4 PRIMARY RESEARCH
    • 3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.5 FORECASTING TECHNIQUES
  • 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.6.1 BOTTOM-UP APPROACH
    • 3.6.2 TOP-DOWN APPROACH
  • 3.7 DATA TRIANGULATION
  • 3.8 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 INCREASING PREVALENCE OF INFECTIOUS DISEASES
    • 4.2.2 ADVANCEMENTS IN MOLECULAR DIAGNOSTIC TECHNIQUES
    • 4.2.3 INCREASING NUMBER OF TRANSPLANT PROCEDURES
  • 4.3 RESTRAINTS
    • 4.3.1 STRINGENT RULES AND REGULATIONS FOR PRODUCT APPROVAL
    • 4.3.2 DEARTH OF SKILLED LABOR
  • 4.4 OPPORTUNITIES
    • 4.4.1 GROWING PUBLIC AWARENESS ABOUT ORGAN DONATION AND TRANSPLANTATION

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D AND DESIGNING
    • 5.1.2 MANUFACTURING
    • 5.1.3 DISTRIBUTION & SALES
    • 5.1.4 POST-SALES SERVICES AND REVIEW
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON GLBOAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
    • 5.3.1 IMPACT ON DEMAND
    • 5.3.2 IMPACT ON SUPPLY CHAIN
    • 5.3.3 IMPACT ON KEY PLAYERS
  • 5.4 QUALITATIVE OVERVIEW FOR INFECTIOUS DISEASE VIRUSES
    • 5.4.1 CYTOMEGALOVIRUS (CMV)
    • 5.4.2 EPSTEIN-BARR VIRUS (EBV)
    • 5.4.3 BK POLYOMAVIRUS (BKV)
    • 5.4.4 HUMAN HERPESVIRUS (HHV-6)
    • 5.4.5 ADENOVIRUS
    • 5.4.6 HERPES SIMPLEX VIRUS (HSV)
    • 5.4.7 PARVOVIRUS
    • 5.4.8 JOHN CUNNINGHAM VIRUS (JCV)
    • 5.4.9 HEPATITIS E VIRUS (HEV)
    • 5.4.10 OTHERS

6 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY PRODUCT

  • 6.1 OVERVIEW
  • 6.2 REAGENTS & KITS
  • 6.3 INSTRUMENTS
  • 6.4 SERVICES & SOFTWARE

7 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY TECHNOLOGY

  • 7.1 OVERVIEW
  • 7.2 POLYMERASE CHAIN REACTION (PCR)
  • 7.3 SEQUENCING
  • 7.4 MICROARRAY
  • 7.5 OTHERS

8 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY END USER

  • 8.1 OVERVIEW
  • 8.2 HOSPITALS AND TRANSPLANT CENTERS
  • 8.3 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
  • 8.4 OTHERS

9 GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET, BY REGION

  • 9.1 INTRODUCTION
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 UK
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA-PACIFIC
    • 9.4.1 JAPAN
    • 9.4.2 CHINA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 MAJOR GROWTH STRATEGY IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • 10.4 THE LEADING PLAYER IN TERMS OF THE NUMBER OF DEVELOPMENTS IN THE GLOBAL MOLECULAR DIAGNOSTICS FOR TRANSPLANT MARKET
  • 10.5 KEY DEVELOPMENT ANALYSIS
  • 10.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
    • 10.6.1 PRODUCT LAUNCH/ PRODUCT APPROVAL
    • 10.6.2 PARTNERSHIP/AGREEMENT
    • 10.6.3 MERGER /ACQUISTION
  • 10.7 FINANCIAL MATRIX
    • 10.7.1 SALES (USD MILLION),
    • 10.7.2 R&D EXPENDITURE (USD MILLION),

11 COMPANY PROFILE

  • 11.1 BIOMERIEUX SA
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCT OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 THERMO FISHER SCIENTIFIC INC.
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCT/SERVICE OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 SWOT ANALYSIS
    • 11.2.6 KEY STRATEGIES
  • 11.3 CEPHEID
    • 11.3.1 COMPANY OVERVIEW
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCT/SERVICE OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 KEY STRATEGIES
  • 11.4 ALTONA DIAGNOSTICS GMBH
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 KEY STRATEGIES
  • 11.5 ELITECHGROUP
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTS
    • 11.5.5 KEY STRATEGIES
  • 11.6 F. HOFFMANN-LA ROCHE LTD
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 SWOT ANALYSIS
    • 11.6.6 KEY STRATEGIES
  • 11.7 HOLOGIC, INC.
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS/SERVICES OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 QIAGEN N.V.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 SWOT ANALYSIS
    • 11.8.6 KEY STRATEGIES
  • 11.9 BECTON, DICKINSON AND COMPANY
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY DEVELOPMENTS
    • 11.9.5 SWOT ANALYSIS
    • 11.9.6 KEY STRATEGIES
  • 11.10 ABBOTT
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS